rAAV production cost analysis: Indication-specific cost per dose and reduction strategies

GENE THERAPY · Published 2026-07-21 · DOI 10.1038/s41434-026-00631-3

Free full text

Authors (4)

Min Tae Park, Dan Matuszek, Angela Andaluz, Seyed Pouria Motevalian

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Park, M., Matuszek, D., Andaluz, A., et al. (2026). rAAV production cost analysis: Indication-specific cost per dose and reduction strategies. GENE THERAPY. https://doi.org/10.1038/s41434-026-00631-3

Related articles

• Applications of genome editing technologies in the treatment of human diseases · GENE THERAPY · 2026 · Same journal
• Ultrasound-guided left heart injection: a safer and more efficient strategy for mouse thoracic aortic gene delivery · GENE THERAPY · 2026 · Same journal
• Optimization and scale up strategies for reproducible AAV enrichment step on CIMmultus® QA HR line · GENE THERAPY · 2026 · Same journal
• Antimicrobial resistance and gene therapy: emerging molecular strategies for a global health threat · GENE THERAPY · 2026 · Same journal
• AAV2 capsid clearance and neuronal trafficking dynamics in the central nervous system · GENE THERAPY · 2026 · Same journal
• Precision rewriting of muscle genetics: therapeutic horizons of base and prime editing in skeletal muscle disorders · GENE THERAPY · 2025 · Same journal
• rAAV8 encapsidated HMR-001/z enables high efficiency hepatic transduction and restores hemostasis in hemophilic mice · GENE THERAPY · 2026 · Same journal
• In vitro and in vivo rescue of dopaminergic neurons in Parkinson’s disease models after Parkin gene therapy · GENE THERAPY · 2026 · Same journal
• Assessment of F/HN-pseudotyped lentiviral vector following intravenous delivery to mice · GENE THERAPY · 2026 · Same journal
• Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma · GENE THERAPY · 2026 · Same journal